• Permanent cookie: Saved on your device for a set period of time. This cookie is used to improve your website experience.
• Session cookie: Stored temporarily in your device’s memory while you visit our website. Session cookies are removed when you close your browser.
• Statistics cookies. These are used by us to track statistics on the number of visitors to our website.
If you do not wish to accept cookies, you can change your browser settings to automatically deny cookies, or to inform you that a website contains cookies. Previously stored cookies can also be deleted via the browser. See your browser's help pages for more information.
If you choose not to accept cookies, some parts of our website may not function optimally for you.
Read more about cookies on The Swedish Post and Telecom Authority website.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our reputable board holds vast experience in drug development, commercialization and company scale-up.
Systemic sclerosis is an autoimmune disease hallmarked by chronic inflammation in the body’s smallest blood vessels.
Half of systemic sclerosis patients develop difficult-to-heal digital ulcers, hampering many everyday activities.
Raynaud’s phenomenon affects most systemic sclerosis patients. It is often the first sign of the disease.
Our lead drug candidate GS-248 is currently under evaluation in a phase 2 study.